[
  {
    "ts": "2025-11-19T08:39:11+00:00",
    "headline": "Business Leaders Set to Welcome Saudi Investments after a Combative White House Meeting",
    "summary": "Saudi Crown Prince Mohammed bin Salman’s overtures to U.S. political and business leaders will continue Wednesday, but on somewhat friendlier terms.  Bin Salman, the de facto ruler of Saudi Arabia, took questions from the press alongside President Donald Trump Tuesday.  The event turned combative after Trump bristled at a reporter’s probing questions.",
    "url": "https://www.barrons.com/livecoverage/trump-government-news-today-111925/card/business-leaders-set-to-welcome-saudi-investments-after-a-combative-white-house-meeting-UqoWDRiDsLI7UAH28pQT?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "e83b0f5d-9c35-30f5-9627-5287709da772",
      "content": {
        "id": "e83b0f5d-9c35-30f5-9627-5287709da772",
        "contentType": "STORY",
        "title": "Business Leaders Set to Welcome Saudi Investments after a Combative White House Meeting",
        "description": "",
        "summary": "Saudi Crown Prince Mohammed bin Salman’s overtures to U.S. political and business leaders will continue Wednesday, but on somewhat friendlier terms.  Bin Salman, the de facto ruler of Saudi Arabia, took questions from the press alongside President Donald Trump Tuesday.  The event turned combative after Trump bristled at a reporter’s probing questions.",
        "pubDate": "2025-11-19T08:39:11Z",
        "displayTime": "2025-11-19T08:39:11Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e83b0f5d-9c35-30f5-9627-5287709da772/business-leaders-set-to.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
          "originalWidth": 320,
          "originalHeight": 65,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dzJ1YBP0KGeG_11a2M96gg--~B/aD02NTt3PTMyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e.cf.webp",
              "width": 320,
              "height": 65,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Yw_3eAv_WYSK2a6PV_FD9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/livecoverage/trump-government-news-today-111925/card/business-leaders-set-to-welcome-saudi-investments-after-a-combative-white-house-meeting-UqoWDRiDsLI7UAH28pQT?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVX"
            },
            {
              "symbol": "QCOM"
            },
            {
              "symbol": "CSCO"
            },
            {
              "symbol": "GD"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "TSLA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T12:08:00+00:00",
    "headline": "Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery",
    "summary": "Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications.",
    "url": "https://finance.yahoo.com/news/nona-biosciences-pfizer-announce-strategic-120800855.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "d7f33c3c-9ff8-308e-8706-32f715d67f8d",
      "content": {
        "id": "d7f33c3c-9ff8-308e-8706-32f715d67f8d",
        "contentType": "STORY",
        "title": "Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery",
        "description": "",
        "summary": "Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications.",
        "pubDate": "2025-11-19T12:08:00Z",
        "displayTime": "2025-11-19T12:08:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/6a508d8f70d7548dd276c1627936c71c",
          "originalWidth": 397,
          "originalHeight": 400,
          "caption": "(PRNewsfoto/Nona Biosciences)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/riS1vfT1UGypIw2tIDYoyQ--~B/aD00MDA7dz0zOTc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6a508d8f70d7548dd276c1627936c71c.cf.webp",
              "width": 397,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AeW5Lrxv89SZQBjBbc_6WQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6a508d8f70d7548dd276c1627936c71c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nona-biosciences-pfizer-announce-strategic-120800855.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nona-biosciences-pfizer-announce-strategic-120800855.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T14:52:00+00:00",
    "headline": "Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies",
    "summary": "Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati",
    "url": "https://finance.yahoo.com/news/ewing-sarcoma-market-research-report-145200339.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "868a97d5-2dea-30d7-bac5-da3b5ea04c73",
      "content": {
        "id": "868a97d5-2dea-30d7-bac5-da3b5ea04c73",
        "contentType": "STORY",
        "title": "Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies",
        "description": "",
        "summary": "Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati",
        "pubDate": "2025-11-19T14:52:00Z",
        "displayTime": "2025-11-19T14:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ewing-sarcoma-market-research-report-145200339.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ewing-sarcoma-market-research-report-145200339.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SLRX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T14:35:00+00:00",
    "headline": "Bacterial Vaginosis Market Research Report 2025-2035, Competitive Analysis of Pfizer, Bayer, Exeltis USA, Lupin, Osel",
    "summary": "The global bacterial vaginosis market is experiencing rapid growth, fueled by a rise in incidence due to lifestyle and hygiene changes. Increasing awareness is driving demand for innovative treatments, including probiotics and precision medicine. Investments from both the government and private sector, especially in women's health, are accelerating market growth. However, challenges such as side effects of current treatments persist. As research advances and emphasis on sustainable solutions int",
    "url": "https://finance.yahoo.com/news/bacterial-vaginosis-market-research-report-143500832.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "95a7fb5e-4d1b-3a32-af6b-616718f32fe1",
      "content": {
        "id": "95a7fb5e-4d1b-3a32-af6b-616718f32fe1",
        "contentType": "STORY",
        "title": "Bacterial Vaginosis Market Research Report 2025-2035, Competitive Analysis of Pfizer, Bayer, Exeltis USA, Lupin, Osel",
        "description": "",
        "summary": "The global bacterial vaginosis market is experiencing rapid growth, fueled by a rise in incidence due to lifestyle and hygiene changes. Increasing awareness is driving demand for innovative treatments, including probiotics and precision medicine. Investments from both the government and private sector, especially in women's health, are accelerating market growth. However, challenges such as side effects of current treatments persist. As research advances and emphasis on sustainable solutions int",
        "pubDate": "2025-11-19T14:35:00Z",
        "displayTime": "2025-11-19T14:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bacterial-vaginosis-market-research-report-143500832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bacterial-vaginosis-market-research-report-143500832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BAYN.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T14:32:00+00:00",
    "headline": "Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck",
    "summary": "The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula",
    "url": "https://finance.yahoo.com/news/metrorrhagia-market-analysis-report-2025-143200224.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "1c6070be-25fb-357a-9b81-dcaab33771a4",
      "content": {
        "id": "1c6070be-25fb-357a-9b81-dcaab33771a4",
        "contentType": "STORY",
        "title": "Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck",
        "description": "",
        "summary": "The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula",
        "pubDate": "2025-11-19T14:32:00Z",
        "displayTime": "2025-11-19T14:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/metrorrhagia-market-analysis-report-2025-143200224.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/metrorrhagia-market-analysis-report-2025-143200224.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "SDZ.SW"
            },
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NBIX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T02:22:33+00:00",
    "headline": "Elon Musk, Jensen Huang to talk AI at US-Saudi investment forum",
    "summary": "WASHINGTON (Reuters) -Tesla CEO Elon Musk and Nvidia CEO Jensen Huang will take part in a discussion on ​advances in artificial intelligence and technology at a U.S.-Saudi ‌Arabia investment forum in Washington on Wednesday, according to a document seen by Reuters.  \"This conversation ‌will explore the emerging forces shaping the next wave of technological progress, highlighting the architectures, models, and investments powering a more intelligent and interconnected future,\" the document said.  The event is planned for the day after Saudi Crown Prince ⁠Mohammed bin Salman, widely ‌known by his initials MBS, met with President Donald Trump at the White House.",
    "url": "https://finance.yahoo.com/news/elon-musk-jensen-huang-talk-022233856.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "83b71e7e-bab5-3eb1-ae31-3ad83ffca505",
      "content": {
        "id": "83b71e7e-bab5-3eb1-ae31-3ad83ffca505",
        "contentType": "STORY",
        "title": "Elon Musk, Jensen Huang to talk AI at US-Saudi investment forum",
        "description": "",
        "summary": "WASHINGTON (Reuters) -Tesla CEO Elon Musk and Nvidia CEO Jensen Huang will take part in a discussion on ​advances in artificial intelligence and technology at a U.S.-Saudi ‌Arabia investment forum in Washington on Wednesday, according to a document seen by Reuters.  \"This conversation ‌will explore the emerging forces shaping the next wave of technological progress, highlighting the architectures, models, and investments powering a more intelligent and interconnected future,\" the document said.  The event is planned for the day after Saudi Crown Prince ⁠Mohammed bin Salman, widely ‌known by his initials MBS, met with President Donald Trump at the White House.",
        "pubDate": "2025-11-19T02:22:33Z",
        "displayTime": "2025-11-19T02:22:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters-finance.com/c873fd50edc1ac3c4faf4827e70d7f19",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KMSVHs9ERjGCjSqKbAwc5w--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/c873fd50edc1ac3c4faf4827e70d7f19.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0QJMhaNR7Nh2GQZ6GKLD_A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/c873fd50edc1ac3c4faf4827e70d7f19.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/elon-musk-jensen-huang-talk-022233856.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/elon-musk-jensen-huang-talk-022233856.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "CSCO"
            },
            {
              "symbol": "BA"
            },
            {
              "symbol": "HAL"
            },
            {
              "symbol": "PSN"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "2222.SR"
            },
            {
              "symbol": "QCOM"
            },
            {
              "symbol": "GD"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "IBM"
            },
            {
              "symbol": "GOOGL"
            },
            {
              "symbol": "CRM"
            },
            {
              "symbol": "SMCI"
            },
            {
              "symbol": "LMT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T16:00:00+00:00",
    "headline": "Pfizer CEO on plans to bring down drug prices",
    "summary": "Pfizer (PFE) CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see lower drug prices. Pfizer is among the companies that have made deals with the White House on pharmaceutical pricing. Make sure to watch Yahoo Finance's full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
    "url": "https://finance.yahoo.com/video/pfizer-ceo-plans-bring-down-160000978.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "c850b3d2-08e5-3185-9529-46830452451d",
      "content": {
        "id": "c850b3d2-08e5-3185-9529-46830452451d",
        "contentType": "VIDEO",
        "title": "Pfizer CEO on plans to bring down drug prices",
        "description": "<p>Pfizer (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>) CEO Albert Bourla sits down with Yahoo Finance Executive Editor <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/author/brian-sozzi/\">Brian Sozzi</a> to talk about when consumers can expect to see lower drug prices. Pfizer is among the companies that have made deals with the White House on pharmaceutical pricing.</p>\n<p>Make sure to watch <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/video/pfizer-ceo-ai-help-medicines-170431756.html\">Yahoo Finance's full interview</a> with Albert Bourla.</p>\n<p>For full interviews, highlights, and key insights, check out more from <a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/topic/yf-invest/\">Yahoo Finance Invest</a>.</p>",
        "summary": "Pfizer (PFE) CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see lower drug prices. Pfizer is among the companies that have made deals with the White House on pharmaceutical pricing. Make sure to watch Yahoo Finance's full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.",
        "pubDate": "2025-11-19T16:00:00Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/4b592be0-c0c9-11f0-b7ef-59e89222f615",
          "originalWidth": 1920,
          "originalHeight": 1080,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QIp8FDfwyewZLsmo5C7JEQ--~B/aD0xMDgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/4b592be0-c0c9-11f0-b7ef-59e89222f615.cf.webp",
              "width": 1920,
              "height": 1080,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B_e8sQD.uMVTwsUfwnKx_g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/4b592be0-c0c9-11f0-b7ef-59e89222f615.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/pfizer-ceo-plans-bring-down-160000978.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/pfizer-ceo-plans-bring-down-160000978.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T16:30:00+00:00",
    "headline": "A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%.",
    "summary": "Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a difference.",
    "url": "https://www.barrons.com/articles/sickle-cell-trial-agios-stock-plunges-640672e4?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "02821833-d0c4-3915-a240-f1737044dea7",
      "content": {
        "id": "02821833-d0c4-3915-a240-f1737044dea7",
        "contentType": "STORY",
        "title": "A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%.",
        "description": "",
        "summary": "Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a difference.",
        "pubDate": "2025-11-19T16:30:00Z",
        "displayTime": "2025-11-19T16:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/02821833-d0c4-3915-a240-f1737044dea7/a-sickle-cell-trial-delivers.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/9d46f5c54ba1591c047c68da847b4656",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KpU8L0MXiPfhQzqw85Ak8Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/9d46f5c54ba1591c047c68da847b4656.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PxQUeiCukXUct0wF7kD4Sw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/9d46f5c54ba1591c047c68da847b4656.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/sickle-cell-trial-agios-stock-plunges-640672e4?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AGIO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T20:59:08+00:00",
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-205908101.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "7aa18ef0-9213-3d2a-81fe-18746163c1f1",
      "content": {
        "id": "7aa18ef0-9213-3d2a-81fe-18746163c1f1",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Softer Late Afternoon",
        "description": "",
        "summary": "Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the",
        "pubDate": "2025-11-19T20:59:08Z",
        "displayTime": "2025-11-19T20:59:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-205908101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-205908101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AGIO"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T05:01:00+00:00",
    "headline": "PFE- The Winner in the Metsera Bidding War",
    "summary": "Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter.",
    "url": "https://finance.yahoo.com/news/pfe-winner-metsera-bidding-war-050100106.html",
    "source": "MoneyShow",
    "provider": "yfinance",
    "raw": {
      "id": "9303e6be-c53f-3427-a814-fab17b194aa0",
      "content": {
        "id": "9303e6be-c53f-3427-a814-fab17b194aa0",
        "contentType": "STORY",
        "title": "PFE- The Winner in the Metsera Bidding War",
        "description": "",
        "summary": "Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter.",
        "pubDate": "2025-11-19T05:01:00Z",
        "displayTime": "2025-11-19T05:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/moneyshow_610/d63ea21516d46b0a792e16b38241f5e4",
          "originalWidth": 453,
          "originalHeight": 193,
          "caption": "A graph of a graph showing the growth of the stock market  AI-generated content may be incorrect.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Np.TDFRiOp25PZbJucY5Vg--~B/aD0xOTM7dz00NTM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/moneyshow_610/d63ea21516d46b0a792e16b38241f5e4.cf.webp",
              "width": 453,
              "height": 193,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FQgjrY6nKTLAzS2Jh_Os5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/moneyshow_610/d63ea21516d46b0a792e16b38241f5e4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MoneyShow",
          "url": "https://www.moneyshow.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfe-winner-metsera-bidding-war-050100106.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfe-winner-metsera-bidding-war-050100106.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T15:38:00+00:00",
    "headline": "Why GRAIL Stock Could Be Biotech’s Next Big Breakout",
    "summary": "Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.",
    "url": "https://www.marketbeat.com/originals/why-grail-stock-could-be-biotechs-next-big-breakout/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "b3f9b3d7-89b5-34b8-a575-d2fac02c152f",
      "content": {
        "id": "b3f9b3d7-89b5-34b8-a575-d2fac02c152f",
        "contentType": "STORY",
        "title": "Why GRAIL Stock Could Be Biotech’s Next Big Breakout",
        "description": "",
        "summary": "Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.",
        "pubDate": "2025-11-19T15:38:00Z",
        "displayTime": "2025-11-19T15:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/a7576054b9fba267cd3763f62905592c",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "Dripping reagent into test tube with blue liquid.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aUtHZOG7MHF0wGXtZaPjg--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/a7576054b9fba267cd3763f62905592c.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rvs0b_elk8B.5sbl_olo6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/a7576054b9fba267cd3763f62905592c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/why-grail-stock-could-be-biotechs-next-big-breakout/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-grail-stock-could-biotech-153800477.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GRAL"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T22:27:00+00:00",
    "headline": "HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?",
    "summary": "Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.",
    "url": "https://www.marketbeat.com/originals/hims-has-been-a-roller-coaster-ride-should-investors-hop-on/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "04766f0d-da44-31d8-b12d-304d4878d04a",
      "content": {
        "id": "04766f0d-da44-31d8-b12d-304d4878d04a",
        "contentType": "STORY",
        "title": "HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?",
        "description": "",
        "summary": "Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.",
        "pubDate": "2025-11-19T22:27:00Z",
        "displayTime": "2025-11-19T22:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/87b0c898b2c826305aa1fff71cc10feb",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Hims and Hers Health logo positioned with telehealthcare provider in background.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oXonfTN0pk8f8goPO_aXwA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/87b0c898b2c826305aa1fff71cc10feb.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hD_1lOhMhdnk19Xy1pnVHQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/87b0c898b2c826305aa1fff71cc10feb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/hims-has-been-a-roller-coaster-ride-should-investors-hop-on/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hims-roller-coaster-ride-investors-222700804.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]